Drugs / BCG Danish
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT04777721 | May 2022 → Jun 2023 | tuberculosis | University of Oxford | Completed | No outcome recorded |
| Phase 1 | NCT03912207 | Apr 2019 → Jun 2024 | tuberculosis | University of Oxford | Unknown | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT06246851 | Apr 2024 → Aug 2028 expected | tuberculosis | University of Oxford | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BCG Danish | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04777721 ↗ |
| Known as | BCG Danish 1331 | “BCG Danish 1331 is on the WHO list of pre-qualified vaccines and has a well-defined side effect profile.” NCT06246851 ↗1“BCG Danish 1331 is on the WHO list of pre-qualified vaccines and has a well-defined side effect profile.” NCT04777721 ↗ |
| Modality | Vaccine | “BCG Danish 1331 is on the WHO list of pre-qualified vaccines and has a well-defined side effect profile.” NCT03912207 ↗ |
| Route | Inhaled | “With BCG Administered by the Intradermal or Aerosol Inhaled Route” NCT03912207 ↗ |